Patents by Inventor Elisabeth Albrecht
Elisabeth Albrecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7271238Abstract: Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.Type: GrantFiled: August 26, 2003Date of Patent: September 18, 2007Assignee: Amylin Pharmaceuticals, Inc.Inventors: Laura S. L. Gaeta, Howard Jones, Elisabeth Albrecht
-
Publication number: 20040038900Abstract: Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.Type: ApplicationFiled: August 26, 2003Publication date: February 26, 2004Inventors: Laura S.L. Gaeta, Howard Jones, Elisabeth Albrecht
-
Patent number: 6610824Abstract: Agonist analogs of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.Type: GrantFiled: December 6, 1999Date of Patent: August 26, 2003Assignee: Amylin Pharmaceuticals, Inc.Inventors: Laura S. L. Gaeta, Howard Jones, Elisabeth Albrecht
-
Publication number: 20020187923Abstract: Agonist analogs of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.Type: ApplicationFiled: December 6, 1999Publication date: December 12, 2002Inventors: LAURA S. L. GAETA, HOWARD JONES, ELISABETH ALBRECHT
-
Patent number: 6051684Abstract: Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R.sub.1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each preferably independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is preferably H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; and X is preferably an aldehyde, .alpha.-ketoester or .alpha.-ketoamide.Type: GrantFiled: May 17, 1995Date of Patent: April 18, 2000Assignee: SIBIA Neurosciences Inc.Inventors: Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz
-
Patent number: 6017887Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: May 18, 1995Date of Patent: January 25, 2000Assignee: Sibia Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 6015879Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; --R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide or aldehyde.Type: GrantFiled: May 17, 1995Date of Patent: January 18, 2000Assignee: Sibia Neurosciences, Inc.Inventors: Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz
-
Patent number: 5998367Abstract: Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.Type: GrantFiled: July 14, 1997Date of Patent: December 7, 1999Assignee: Amylin CorporationInventors: Laura S. L. Gaeta, Howard Jones, Elisabeth Albrecht
-
Patent number: 5969100Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: March 13, 1995Date of Patent: October 19, 1999Assignee: SIBIA Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5962419Abstract: Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R.sub.1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each preferably independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; Q is preferably --C(O)--; R.sub.B is preferably iso-butyl; R.sub.A is --(T).sub.m --(D).sub.m --R.sub.1, in which T is preferably oxygen or NH, m is 0 or 1, and D is preferably C.sub.1-4 alkyl or C.sub.2-4 alkenyl; and X is preferably an aldehyde, .alpha.-ketoester or .alpha.-ketoamide.Type: GrantFiled: May 17, 1995Date of Patent: October 5, 1999Assignee: SIBIA Neurosciences, Inc.Inventors: Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz, Blake Alan Rowe, Robert Steven Siegel, Steven Lee Wagner
-
Patent number: 5872101Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: May 18, 1995Date of Patent: February 16, 1999Assignee: Sibia Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5863902Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; RB is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.Type: GrantFiled: May 18, 1995Date of Patent: January 26, 1999Assignee: Sibia Neurosciences, Inc.Inventors: Benito Munoz, Ian A. McDonald, Elisabeth Albrecht
-
Patent number: 5804560Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 -(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m--(D).sub.m--R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide or aldehyde.Type: GrantFiled: January 6, 1995Date of Patent: September 8, 1998Assignee: SIBIA Neurosciences, Inc.Inventors: Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz
-
Patent number: 5686411Abstract: Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.Type: GrantFiled: May 23, 1995Date of Patent: November 11, 1997Assignee: Amylin Pharmaceuticals, Inc.Inventors: Laura S. L. Gaeta, Howard Jones, Elisabeth Albrecht
-
Patent number: 5580953Abstract: Compounds which inhibit amylin activity are provided. These compounds may be used in the treatment of conditions where it is of benefit to reduce amylin activity, including the treatment of Type 2 diabetes mellitus, impaired glucose tolerance, obesity and insulin resistance.Type: GrantFiled: November 19, 1991Date of Patent: December 3, 1996Assignee: Amylin Pharmaceuticals, Inc.Inventors: Elisabeth Albrecht, Howard Jones, Laura S. L. Gaeta, Kathryn S. Prickett, Kevin Beaumont
-
Patent number: 5424394Abstract: Synthetic amylin and amylin analogs which have high biological activity and which are substantially free from deletion peptides and other contaminating peptides are provided. Also provided are methods for the solid phase peptide synthesis of amylin and amylin analogs.Type: GrantFiled: July 8, 1993Date of Patent: June 13, 1995Inventors: Laura S. Lehman de Gaeta, Elisabeth Albrecht